Trade Summary

1 week ago, Murphy Polly A., serving as Dir at Atea Pharmaceuticals, Inc. (AVIR), purchased 6,100 shares at $4.17 per share, for a total transaction value of $25,446.00. Following this transaction, Murphy Polly A. now holds 92,145 shares of AVIR.

This purchase represents a 7.00% increase in Murphy Polly A.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, May 18, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, May 21, 2026 at 6:30 PM ET, 3 days after the trade was made.

Atea Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.